|
Non-metastatic prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we studied the impact of advanced PET image-reconstruction methods on BCR localization and interobserver agreement with <sup>18</sup>F-DCFPyL PET/CT scans in patients with BCR and low PSA values.
|
31481580 |
2020 |
|
Non-metastatic prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prostate specific membrane antigen targeted radiotracers are likely effective to detect biochemically recurrent prostate cancer at low prostate specific antigen levels.
|
30829130 |
2019 |
|
Non-metastatic prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we evaluate the lesion detection efficacy of <sup>18</sup>F-DCFPyL PET/CT in patients with BCR and determine the detection efficacy as a function of their PSA value.
|
31230088 |
2019 |
|
Non-metastatic prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<b>Conclusion:</b><sup>18</sup>F-DCFPyL-PET/CT imaging offers high detection rates in biochemically recurrent prostate cancer patients; and is positive in about 50% of patients with PSA <0.5 ng/mL, which could substantially impact clinical management.
|
31676732 |
2019 |
|
Non-metastatic prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.
|
31530439 |
2019 |
|
Non-metastatic prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consenting treatment-naïve patients with cT3, Gleason 8-10, or prostate-specific antigen > 20 ng/mL and non-metastatic prostate cancer were included.
|
31416141 |
2019 |
|
Non-metastatic prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with biochemically recurrent prostate cancer and short prostate-specific antigen doubling time (PSADT) are at risk for metastasis yet may wish to avoid androgen deprivation therapy.
|
30327180 |
2019 |
|
Non-metastatic prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This was a phase II, Simon 2-stage clinical trial in patients with biochemically recurrent prostate cancer with a primary endpoint of prostate-specific antigen (PSA) response.
|
30289005 |
2018 |
|
Non-metastatic prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oncological and peri-surgical outcomes of radical prostatectomy for non-metastatic prostate cancer with prostate-specific antigen level of 50 ng/ml or greater.
|
29635526 |
2018 |
|
Non-metastatic prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The findings suggest that a fully powered study of this combination is feasible in men with biochemically recurrent prostate cancer and a moderate PSA rise rate.Prostate 77:765-775, 2017.
|
28181675 |
2017 |
|
Non-metastatic prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To compare clinical features, treatments and outcomes in men with non-metastatic prostate cancer (PCa) according to whether they were referred for symptoms or elevated prostate-specific antigen (PSA) level.
|
27489140 |
2017 |
|
Non-metastatic prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<b>Purpose:</b> STAND, a randomized, phase II, open-label trial (NCT01431391), assessed sequencing of sipuleucel-T (an autologous cellular immunotherapy) with androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC) patients at high risk for metastasis.<b>Experimental Design:</b> Men with BRPC following prostatectomy and/or radiotherapy, a PSA doubling time ≤12 months, and no metastasis were enrolled.
|
27836866 |
2017 |
|
Non-metastatic prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three week nutritional interventions with tomato-products alone or in combination with selenium and n-3 fatty acids lower PSA in patients with non-metastatic prostate cancer.
|
27406859 |
2017 |